FY2025 · ended Dec 31, 2025 · Revenue $502.08M, +126.3% YoY · Filed Feb 24, 2026
BridgeBio Pharma, Inc. (BBIO) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $502.1 million and a net loss of $732.9 million. Free cash flow was -$447.0 million. As of Sep 30, 2026 it held $1.5 billion in cash and investments and $2.6 billion in total debt.
Revenue (TTM)
$945.54M
+167.3% vs year-ago TTM
Net income
$-732.94M
-34.9% vs prior year
Operating cash flow (TTM)
$-368.97M
+36.9% vs year-ago TTM
Free cash flow (TTM)
$-369.81M
+36.9% vs year-ago TTM
EPS (TTM)
$-3.04
+27.4% vs year-ago TTM
Dividend per share
None
Shares outstanding
193.86M
+1.9% vs prior year
Net cash
$-1.11B
as of Sep 30, 2026
Operating margin
-38.5%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- BBIO (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Palo Alto, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1743881
- Former names
- BridgeBio Pharma LLC (until May 16, 2019)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $502.1M | $221.9M | $9.3M | $77.6M | $69.7M |
| Operating income | -$523.4M | -$593.0M | -$607.4M | -$512.2M | -$576.6M |
| Net income | -$732.9M | -$543.3M | -$653.3M | -$484.7M | -$586.5M |
| Diluted EPS | -$3.78 | -$2.88 | -$3.95 | -$3.26 | — |
| Operating cash flow | -$445.9M | -$520.7M | -$527.7M | -$419.5M | -$497.9M |
| Free cash flow | -$447.0M | -$521.7M | -$529.0M | -$424.3M | -$511.2M |
| Total assets | $936.0M | $919.3M | $546.4M | $623.0M | $1.0B |
| Total liabilities | $3.0B | $2.4B | $1.9B | $1.9B | $1.9B |
| Stockholders' equity | -$2.1B | -$1.5B | -$1.4B | -$1.3B | -$870.4M |
| Cash and investments | $587.5M | $681.1M | $375.9M | $428.3M | $787.5M |
| Total debt | $2.0B | $446.5M | $459.6M | $446.9M | $454.7M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Oct 29, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Oct 29, 2026 | Oct 29, 2026 |
| 8-K |
Current report
Other events
|
Oct 13, 2026 | Oct 6, 2026 |
| 8-K |
Current report
Other events
|
Aug 31, 2026 | Aug 31, 2026 |
| 8-K |
Current report
Material agreement, Other events
|
Aug 17, 2026 | Aug 13, 2026 |
| 10-Q | Quarterly report | Aug 10, 2026 | Jun 30, 2026 |
All 833 BridgeBio Pharma, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.